Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 13 Publications

3 Customer Reviews

  • Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

  • Immunofluorescence staining of LC3 protein expression of U2OS cells treated with DMSO (negative control), Rap (positive control, 500 nM), Tha (1 μM), Tun (2 μg/mL), BFA (10 μg/mL), and DTT (4 mM) for 8 h. Immunoblot of ER-phagy-related proteins of U2OS cells treated with four ER stress inducers.

    Nanoscale, 2018, 10(18):8796-8805. Brefeldin A purchased from Selleck.

  • CSFV proliferation in ST cells with or without BFA was observed by IFA at 24, 48 and 72 hpi.

    J Biosci, 2018, 42(1):43-56. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 M3f5c2Z2dmO2aX;uJGF{e2G7 M331e|Ih|ryP M1fWWFEhcA>? MmTpbY5pcWKrdIOgeIhmKExvRF;QRUApOjEEoN88UUkucW6mdXPl[EB1emGwc3nlcpQhTVKNMT:yJJBpd3OyaH;yfYxifGmxbtMg NGfSO2UzPjN4M{G5NS=>
C2C12 M{e2UmZ2dmO2aX;uJGF{e2G7 MoPINeKh|rypL33s NGHncJAyyqCq MlHMZYJwdGm|aHXzJIN6fG:taX7lJJJmdGWjc3Wg[pJwdSCFMlOxNkBugW:2dXLldy=> M{DB[lI3OjlzMke5
MEFs WT MWfGeY5kfGmxbjDBd5NigQ>? MknPOeKh|ryP M{njNFIxKG2rbh?= MU\jZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT M{izVVI3OTl4MEKz
MEFs VAMP7 KO M3j3OmZ2dmO2aX;uJGF{e2G7 MXW1xsDPxE1? MnvZNlAhdWmw NWLSclZn[2G3c3XzJJJme2mmZX70JIVvgnmvZYOgd5VkcCCjczDORWdVNUeIUDygeI8h\GmoZoXz[UBj[WOtIITvJJRp\SCHUh?= MVeyOlE6PjB{Mx?=
SMCs NXrGTWx7TnWwY4Tpc44hSXO|YYm= M3r5Z|ExyqEEtXevcYw> MYWwMVEzKGh? Mke0SG1UVw>? M2PRSZNpd3e|IHGgeJJmdmRidH;3ZZJleyCjIHjp[4hmeiClb37j[Y51emG2aX;uJI9nKHSqZTDFVk9UWiCwZYT3c5JsKGmwIITo[UBx\XKrboXjcIVieiCjcnXhxsA> NGXRN5QzPjF5MkC4NC=>
SMCs NFHsdmNHfW6ldHnvckBCe3OjeR?= NHmxe3oyOMLiwsXnM41t MWGwMVEzKGh? MYfEUXNQ M1LGV4NifXOnczDhJJRz[W6|aXXueEBE[TJtwrDy[Yxm[XOnIH\yc40hfGinIFXSM3NTyqB? MmWyNlYyPzJyOEC=
HEMC-1 MnHZSpVv[3Srb36gRZN{[Xl? NXHkOVBjOC5zwrFCuYcwdWx? M{e4d|I1yqCq MYHjZZV{\XNiYTDobYdp\XJiaX7obYJqfG:{eTDl[oZm[3Rib36g[Zhw[3m2b4Ppd{B1cGGwIH7vZ49l[XqxbHW= Mk\4NlU6PzJ5NUm=
HUVEC MkPLSpVv[3Srb36gRZN{[Xl? NXv4bYxtOTEEoN88US=> M2Dzc|HDqGh? MXnEUXNQ MVvhZo9tcXOqZYOgbJlxd3irYT3pcoR2[2WmIILlcIVie2Vib3[gRXRRKG[{b32gZZBq[2GuIHHu[EBj[XOxbHH0[ZJidCC|dYLmZYNmew>? M2P1OlI2QTV4OUi4
HUVEC Mo\zSpVv[3Srb36gRZN{[Xl? MVGxNOKh|ryP Mn;sNeKhcA>? MnHDSG1UVw>? MUXpcoNz\WG|ZYRCpJRp\SCwdX3i[ZIh[W6mIHnueIVve2m2eTDv[kBndHWxcnXzZ4VvfCCjcnXhd{Bme3CnY3nhcIx6KGmwIIDldolvfWOuZXHyJJNx[WOn Mmn4NlU6PTZ7OEi=
Caco-2 M37ZWmZ2dmO2aX;uJGF{e2G7 MXmyMlUh|ryP M1vVb|MxKG2rbh?= NWj5bo42[XS2ZX71ZZRmeyC2aHWgWGdHNc7{MT3t[YRq[XSnZDDpcoNz\WG|ZTDpckBUTVKWIH\1coN1cW:w M16ySVI2QTV2OUOx
NRK MVHGeY5kfGmxbjDBd5NigQ>? MoXpNlAx6oDHbnevcYw> NYXaRYExPOLChXi= NXLOd2JlTE2VTx?= NFnS[3Nz\XOldXXzJI1qfG:2aXOgdJJw\3Knc4Ppc44> M4rYZlI2QTR6NUi2
HeLa M3fsXWZ2dmO2aX;uJGF{e2G7 NHvSU|MzODEkgJXu[{9udA>? M2j3UVMhcA>? MVzEUXNQ MXzpcoR2[2W|IITo[UBienSrZnnjbYFtKGK{ZXHrMZVxKG:oIITo[UBId2ypaTDjc41xdGW6 M{\BOVI2QTR6NUi2
COS M3fZNGZ2dmO2aX;uJGF{e2G7 NGLMVFMyKM7:Zz;tcC=> MYizJIg> M4niUoNwdXCuZYTlcJkh\Gm|cHXyd4V{KHSqZTDBVE0yKHOrZ37hcOKh NWDLZmlHOjV7MUW5NFA>
DF1  MVPGeY5kfGmxbjDBd5NigQ>? M{HuNFHDqM7:TdMg MmD1OFghcA>? NYK2XZhHTE2VTx?= NUW5cppF\Gm|cHXyd4V{yqC2aHWg[Zhw\2Wwb4XzJGNUT2GuTlHjWFIheHKxdHXpci=> MnLvNlU5ODdyNUS=
nHDFs  MUjGeY5kfGmxbjDBd5NigQ>? NVriW4FEOcLizszNxsA> NVTUTZBNOsLiaB?= MkHFdJJmfmWwdIOgeIhmKGG|c3XtZox6KG:oIHP5eI9{d2yrYzDjc4F1KHC{b4TlbY5{KG:wdH:gS49t\2libXXtZpJidmW| MVyyOVc4OjZzNh?=
FRT  NWXNb5JCTnWwY4Tpc44hSXO|YYm= M1;2WVUh|rypL33s NXTubVlSOsLiaB?= NELyRodjdG:la4OgeJJi\m[rY3vpcochfGi{b4XnbEB1cGViR3;s[4kh[2:vcHzlfEBjgSCrbnjpZol1cW6pIFXSMZRwNUexbHfpJJRz[W6|cH;yeC=> MnyyNlU4PjdzMUW=
FRT  MXXGeY5kfGmxbjDBd5NigQ>? MV61JO69\y:vbB?= Mn;nNuKhcA>? MmHWdJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIHPs[YF3\WRizsGgd5VjfW6rdIOge4hmdiCdTnGrYYnDqHejczDy[YR2[2Wm MYeyOVc3PzFzNR?=
HepG2  MV;GeY5kfGmxbjDBd5NigQ>? NFHYXWwy6oDLwsXNxsA> M3n6flI1KGh? MXvEUXNQ MlKx[IVkemWjc3XzJJRp\SCuZY\lcEBw\iCSWGKgcXJPSQ>? NFjzd|YzPTZzNkW5Oy=>
SMCs MVvGeY5kfGmxbjDBd5NigQ>? MVux{txoN22O NH3zUVA{KGh? NGXxPW1i[2O3bYXsZZRmeyCFTmDZNkBxem:2ZXnuJIlvKHSqZTDFVkBkd22yYYL0cYVvfCCjbnSgco8hdG:wZ3XyJINwNWyxY3HsbZpm\CC5aYToJJRp\SCJb3znbUBu[XKtZYNCpC=> MYiyOVU5QTR{NR?=
OB-6 M1m3fmFxd3C2b4Ppd{BCe3OjeR?= NUT5SHBiOi55wrFOwG0> MVW0PEBp MlntbY5lfWOnczDhdI9xfG:|aYO= NYLXeWFuOjV3M{K0PFA>
iPSC-CMs  NVX3NGVxTnWwY4Tpc44hSXO|YYm= NFTXb4U2ODBibnevcYw> M3XDcVQ5KGh? M37VbIlv[3KnYYPld{B1cGViaX70[Y5{cXS7IH;mJJRp\SCqaXfo[ZIhdW:kaXzpeJkhVEGPUIOgZZQhfGinIHPvd5Qhd2ZidHjlJIxwf2W{IH3vZoltcXS7IIPw[YNq\XN? M2i1Z|I2PDh6Nk[2
SP-Nluc M3\aeWZ2dmO2aX;uJGF{e2G7 M{HVOlUhdWdxbVy= MmDvOkBp MnLlSG1UV8Li NYfPWppR[2G3c3XzJIFvKGmwY4LlZZNmKGmwIILldI9zfGW{IHHjeIl3cXS7IHnuJJRp\SCyYYLhd4l1\Q>? NFrLSWUzPTN7Mkm5PC=>
PEXEL-Nluc NGH4TYVHfW6ldHnvckBCe3OjeR?= NV\VfVFSPSCvZz;tUC=> NF\XZ3c3KGh? MkK1SG1UV8Li MV\jZZV{\XNiYX6gbY5kemWjc3WgbY4hemWyb4L0[ZIh[WO2aY\peJkhcW5idHjlJJBiemG|aYTl NXu0NWtSOjV|OUK5PVg>
H1299 M{jsO2Z2dmO2aX;uJGF{e2G7 MWexNEDPxGdxbXy= M1SxclI1KGh? Ml\wbY5lfWOnczDheZRweGijZ4pCpC=> NIDDb2EzPTN6OEm3NC=>
MDA-MB-231 M{nBdmNmdGxiVnnhZoltcXS7IFHzd4F6 M3TIblDjiJN3MDFOwIcwdUx? NXTkdZlHPDhiaB?= MWPFR|UxyqB;IECuNFE3KML3Zz;tUC=> MXeyOVM2PjV4Nx?=
MDA-MB-231 MVjBdI9xfG:|aYOgRZN{[Xl? MljsNE4yKM7:Zz;tUC=> NH3xOmg1KGh? NVXse4FpcW6mdXPld{BieG:ydH;zbZM> NYK0WY46OjV|NU[1Olc>
MDA-MB-231 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7zb3RmOC5yMT:wMlA2KM7:Zz;tUC=> MlfDNlQhcA>? NWP5d4RscW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kB{fWJvR{GgZ4VtdCCmZXLybZM> MX6yOVM2PjV4Nx?=
MDA-MB-231 Mn3ERZBweHSxc3nzJGF{e2G7 NYPRNG1zOC5yNfMAl|Eh|rypL33M MkD6NlQhcA>? Mn3lbY5lfWOnczDQRXJRKCiyb3z5JGFFWC2{aXLvd4UheG:ueX3ldoF{\S1zKTDjcIVifmGpZR?= NH3zSJUzPTN3NkW2Oy=>
MDA-MB-231 NVP6OoVtTnWwY4Tpc44hSXO|YYm= M2DjTlDjiJN3MDFOwIcwdUx? NETifXYzPCCq MWTpcohq[mm2czD0bIUh\m:{bXH0bY9vKG:oIEPEJIFv\CB{RDDjc4xwdmmncx?= NXK4VIVJOjV|NU[1Olc>
A172 MVPGeY5kfGmxbjDBd5NigQ>? MmjENVDDqM7:Zz;tcC=> MYe0xsBp MXXEUXNQyqB? MoPxdoV{fWy2czDpckB1cGVicnX0do9oemGmZTD0doFve3CxcoSgc4Yh\my3b4Lld4NmdnRiZ4LhcpVt\XN? NXn2[JlDOjV{M{m1NFc>
KMS-6 NVL2bot2TnWwY4Tpc44hSXO|YYm= M2nF[VHDqM7:TdMg Mk\kNlQhcA>? MUXlfIhq[mm2czDoZYxnKHSqZTDz[YNz\XSrb36gc4Yh\2GuYX7pck1NUSCjczDkbYQhfGinIHPvcpRzd2x? NUPzeWZbOjV{MkmxNlY>
MEC M3W3e2Z2dmO2aX;uJGF{e2G7 NGDxemUyKM7:TR?= NU\PcFRGOS53IHi= MnXwZ4F2e2W|IHGg[JJidWG2aXOg[IVkemWjc3WgbY4hfGinIIP1doZi[2ViVlXHSnIz M3vDOFI2OjJ6OEG1
HEK293/hERG NUHFe41WTnWwY4Tpc44hSXO|YYm= M2PYTlExyqEQvF2= MXixxsBp MXTy[ZN2dHS|IHnuJIEhfGmvZT3k[ZBmdmSnboSgdoVlfWO2aX;uJI1ifHW{ZTDoSXJIKHC{b4TlbY7DqA>? NYXPOIJnOjV{MUi0Olk>
RBE4 M{f3UmFxd3C2b4Ppd{BCe3OjeR?= M1LlcVLDqM7:TR?= NHvLfG8{6oDVMkVCpIg> MWrpcoR2[2W|IHHwc5B1d3OrczD0bY1mKGSncHXu[IVvfGy7 NW\Cfm9{OjVzMkiwNlU>
RBE4 MnHVSpVv[3Srb36gRZN{[Xl? MnzKNuKh|ryP MWKz5qCUOjUEoHi= M{LsRYlv[3KnYYPld{B1cGViWFLQNUBxem:2ZXnuJIxmfmWuczDh[pRmeiB|IHHu[EA3yqCqIH;mJJRz\WG2bXXueC=> MWmyOVEzQDB{NR?=
RBE4 NHPJdYNHfW6ldHnvckBCe3OjeR?= NWDFZnJmOsLizszN NGXqeVg{6oDVMkVCpIg> MWnpcoNz\WG|ZYOgZYN1cX[nIHPhd5Bie2VvMUKgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=> NFvYZ3YzPTF{OECyOS=>
RBE4 NFvjXIdHfW6ldHnvckBCe3OjeR?= NV3RXHVROsLizszN M{PjS|PjiJN{NNMgbC=> MYLpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCUT2OgeIlu\S2mZYDlcoRmdnSueR?= M{myPFI2OTJ6MEK1
RBE4 NXfzdIJnTnWwY4Tpc44hSXO|YYm= M4r2fVLDqM7:TR?= NG[xfG8{6oDVMkVCpIg> MV7pcoR2[2W|IHGg[IVt[XmnZDDk[ZBt\XSrb36gc4YhfGinIFXSJGNiOiwEoHPvcpRmdnRiYYSgOuKhcCCxZjDpcoN2[mG2aX;uJJNq\26rZnnjZY51dHl? MlH1NlUyOjhyMkW=
RBE4 NH3LbWpHfW6ldHnvckBCe3OjeR?= NF3ZNWUzyqEQvF2= MmexN-KBmzJ2wrDo M3jxRYlv\HWlZYOgZY4hd3[ncnzvZYQhd2ZiQ3GyL:KhcW5idHjlJI1qfG:laH;u[JJq[SCrbjD0bIUh\mm{c4SgOuKhcCCxZjDpcoN2[mG2aX;uJEhx6oDLPPMAjVAvODBzKTDieZQhS2F{K9MgcIV3\Wy|IHnuJJRpcXNib4LnZY5mdGynIHTlZ5Jm[XOnZDDh[pRmeiBzMtMgbEBw\iCrbnP1ZoF1cW:w NVvPN496OjVzMkiwNlU>
Huh-7  M2DTZWZ2dmO2aX;uJGF{e2G7 MYKx{txoN22O M1nSUFPjiJN{NNMgbC=> NVy3blBkcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDBVGUyKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz NV[2bYpPOjVyMk[xO|Q>
HepG2  MoDGSpVv[3Srb36gRZN{[Xl? NIDvWoMy|rypL33M MojRN-KBmzJ2wrDo MYLpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NUfCV5BROjVyMk[xO|Q>
H838-LKB1 MX7GeY5kfGmxbjDBd5NigQ>? MoXoN|DDqG6pL33s NHfwbHgyOi9zODDo MYTpcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKEKrUNMg NGXD[48zPTBzMUC4Ni=>
H838-KDLKB1  MkLVSpVv[3Srb36gRZN{[Xl? MonhN|DDqG6pL33s MUKxNk8yQCCq Mn7YbY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=> NUfRNpB3OjVyMUGwPFI>
H838-KDLKB1  MkG0SpVv[3Srb36gRZN{[Xl? NF3Bc5Y{OMLibnevcYw> MnnKNVIwOThiaB?= Mom0bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicHjvd5Bpd3K7bHH0[YQh\UmIMt8xJEhxcG:|cHjvMYVKTjMQsTm= NGf5RpUzPTBzMUC4Ni=>
3T3-L1 Mn7aSpVv[3Srb36gRZN{[Xl? MlvrOUDPxGdxbXy= NVPzWIlXOzBibXnu MlTmcYlucWO|IITo[UBm\m[nY4TzJI9nKGmwc4XsbY4h[W6mIHPheZNmeyC{b3L1d5QheGixc4Doc5J6dGG2aX;uJI9nKEGtdDCoV4VzKDR5MzmgZY5lKHCqb4PwbI9zgWyjdHnvckBw\iCDU{G2NEApXGi{IE[0NkBidmRiU3XyJFU5QCl? NVTu[Gh2OjR6NEO4Nlc>
3T3-L1 M{L3T2Z2dmO2aX;uJGF{e2G7 NF;ufHk2KM7:Zz;tcC=> MmG0N|AhdWmw MXfy[YNieGm2dXzheIV{KGmwc4XsbY4h[WO2aX;uJJdqfGhicnXzdIVkfCC2bzDy[Yd2dGG2aX7nJGFsfCCjY4Tpeol1gSCjbnSgRXMyPjBicHjvd5Bpd3K7bHH0bY9v NHzpfGIzPDh2M{iyOy=>
3T3-L1 MkizSpVv[3Srb36gRZN{[Xl? NVmyTpZiPSEQvHevcYw> NIrTXFI{OCCvaX6= NEC4VFBk[XW|ZYOgdoV3\XK|aXLs[UBz\WSrc4TybYJ2fGmxbjDv[kBIVFWWNB?= NFvyfoUzPDh2M{iyOy=>
3T3-L1 NUnKfllYTnWwY4Tpc44hSXO|YYm= M3LaPFUh|rypL33s NUPjZ2ZZOcLiaB?= MWLjZZV{\XNicnXkbZN1emmkdYTpc44hd2ZiR1zVWFQh[nW2IH7veEBqdmO{ZXHz[UBqdiCpbIXjc5NmKHWydHHr[S=> NWTUdJE3OjR6NEO4Nlc>
3T3-L1 M{m0PWZ2dmO2aX;uJGF{e2G7 NYq3Z2pnPSEQvHevcYw> NH3sbY0yyqCq MmPlZ4F2e2W|IIDoc5NxcG:{eXzheIlwdiCxZjD0bIUhTm:6T{GgeJJidnOlcnnweIlwdiCoYXP0c5I> NGPkXJAzPDh2M{iyOy=>
HeLa  NH7kR2JHfW6ldHnvckBCe3OjeR?= NYDaepVjPSEQvHevcYw> M2C2O|MhcA>? NILmNGZk[XW|ZYOgcpVkdGWjcjDlfINtfXOrb36gc4YhfGinIF\vfG8yKHS{YX7zZ5JqeHSrb36g[oFkfG:{IHHu[EBl\WO{ZXHz[ZMhfHKjboPjdolxfGmxbjDv[kBHd3iRMT3y[Yd2dGG2ZXSg[4Vv\XN? M1jjelI1QDR|OEK3
HEK293 MU\GeY5kfGmxbjDBd5NigQ>? MU[1xsDPxGdxbXy= NWfadJkxOTMEoHi= MmXqZYJwdGm|aHXzJGNOSS2rbnT1Z4VlKEOURVzENkB{\WO{ZYTpc44> MWWyOFY5PzR|MR?=
COS-1 M{jJb2Z2dmO2aX;uJGF{e2G7 MlP3OUDDvWdxbXy= NYq4PWRGOjRiaNMg NHjje3Vz\XO2cnnjeJMhdG:lYXzpfoF1cW:wIH;mJG5DKGmwIITo[UBx\XKrboXjcIVieiC{ZXfpc47DqA>? MWKyOFY4OTd3MR?=
PRP NWT4R5VDTnWwY4Tpc44hSXO|YYm= NFTyeZYyOCEQvF2= NIXWbZZi[nKxZ3H0[ZMhW0SILUJOtU1u\WSrYYTl[EBEYEOUNzDlfJRmem6jbHn6ZZRqd28EoB?= Mmi0NlQ3Pjh5NUC=
RAW264.7 NF\BSmxCeG:ydH;zbZMhSXO|YYm= MWm0JO69VQ>? MmXPOFghcA>? M3LUZoF1fGWwdXH0[ZMhfGinIHnubIljcXSrb36gc4Yhd3hvTFTMMYlv\HWlZXSgZZBweHSxc3nzJIFv\CC2aHWg[oFkcWyrdHH0bY9vKG:oIHPoc4xme3Sncn;sJIVn\my3eDDifUBC[y2qRT2xPGEuVkh{ NX:zc5o2OjR4M{mwN|I>
MDMs M3;uVGFxd3C2b4Ppd{BCe3OjeR?= NFrBXJgyOOLCid88[{9udA>? NWnuNm5HOTJxMUWgbC=> M4PnXIlv\HWlZYOgZZBweHSxc3nz NEHhN4szPDV3Nk[5OS=>
PMHs  MVfGeY5kfGmxbjDBd5NigQ>? MnLiNVDjiJN{MPMAje69\y:vbB?= NUDTWY91OjUkgJno MYHEUXNQ M1n2Oolv\HWlZXSgSXIhe3S{ZYPz M2LJeVI1PDB5MkSy
PMHs  NWjMcG06SXCxcITvd4l{KEG|c3H5 MojMNVDjiJN{MPMAje69\y:vbB?= MWCyOQKBkWh? MXnEUXNQ NFLxepNqdmO{ZXHz[ZMh[2WubDDk[YF1cA>? NVHKTnZSOjR2MEeyOFI>
HEK293/tau NHnkfIFHfW6ldHnvckBCe3OjeR?= NX3KcJdDPSEQvF2= MoewNU8zNzRiaB?= MmLLbY5lfWOnczDHc4xocSCocnHncYVvfGG2aX;uxsA> M4HyVVI1OzZ6MEi5
HEK293/tau MlnQSpVv[3Srb36gRZN{[Xl? NI\n[oc2KM7:TR?= NU\kXoZPOyCq MXLpcoR2[2W|IITheUBpgXCncoDoc5NxcG:{eXzheIlwdg>? Ml[xNlQ{PjhyOEm=
ADF NGD4OWhHfW6ldHnvckBCe3OjeR?= NX[5[YdJOTBizszN NEHqOXIyPiCq Mmj4bY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> NHrLUHYzPDJ{OEKzNi=>
U373  M175NWZ2dmO2aX;uJGF{e2G7 M1vQc|ExKM7:TR?= MmfxNVYhcA>? NFzLSFdqdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? MmXMNlQzOjh{M{K=
RKO-HIPK2i MojhSpVv[3Srb36gRZN{[Xl? MYSxNEDPxE1? MVyxOkBp MlLUbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> NF;BWFQzPDJ{OEKzNi=>
ADF  NGTHXWhHfW6ldHnvckBCe3OjeR?= NIPIRW0yOCEQvF5CpC=> Mn\xOkBp NHfSeXBqdXCjaYLzJJRp\SCGQzDhZ5RqfmG2aX;u NVfqb2ozOjR{MkiyN|I>
Huh7 MVTGeY5kfGmxbjDBd5NigQ>? NF;5Slc2KM7:Zz;tcC=> NWXOS5JzPCCq M1PlSYFjd2yrc3jld{B1cGVic3XjdoV1cW:wIH;mJEBqdnS{YXPlcIx2dGG{IFHwc2I> M1HCS|I1OTByMUSw
Huh7 NVXnT3hoTnWwY4Tpc44hSXO|YYm= MoHhOUDPxGdxbXy= MX[xJIg> NWf1VWJz[2G3c3XzJIEhe2mpbnnmbYNidnRiaX7jdoVie2ViaX6gRZBwSi2lcnXzZ4VvfHN? NF25[2EzPDFyMEG0NC=>
Huh7 NXPYZWdWTnWwY4Tpc44hSXO|YYm= NETrTZE26oDVMUFCpI5oN22u NH\nb5UyOiCq MYPpcoNz\WG|ZYOgRZBwSi2lcnXzZ4VvfHNid3n0bI92fCCrbnjpZol1cW6pIIPlZ5JmfGmxbh?= NVjSW4FpOjRzMECxOFA>
BAECs NWXpPY9STnWwY4Tpc44hSXO|YYm= MYS1JO69\y:vbB?= MXqwMVQhcA>? M{jQXIlv\HWlZYOgeIhmKHKjcHnkJIRmeGixc4Doc5J6dGG2aX;uJI9nKGWQT2OgZZQhW2W{MUG3PS=> Ml7lNlQxQDV{MkW=
Macrophages MlTySpVv[3Srb36gRZN{[Xl? MXm3NUDDvU1? NHnVbZI3KGh? MojrbY5pcWKrdIOgcJVv[XOrbjDpcpRmem6jbHn6ZZRqd28EoB?= MVqyOFA{QTd2MB?=
Colo 205 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjaWGMxNTVizsznM41N NWSzXJpHPDhiaB?= MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiC|dYPw[Y5{cW:wIHP1cJR2emW|IIfpeIgh[W5iZYP0bY1ifGWmIFnDOVAhd2ZifkG1JI5oN22O MWOyN|k4Ozl7Nh?=
Colo 205 MYXGeY5kfGmxbjDBd5NigQ>? MoDZNE4xOTJvMD6wNlUh|rypL33M MXmxOEBl MYLy[YR2[2W|IITo[UBkdG:wb3flcolkcXS7IH;mJGNwdG9iMkC1JGNUS3N? MYOyN|k4Ozl7Nh?=
Colo 205 NWnNV2dlSXCxcITvd4l{KEG|c3H5 MWGwMlEh|rypL33M M3vIVlAuOjRiaB?= NV3uVVZLcW6mdXPld{BieG:ydH;zbZMhd2ZiQ3;sc{AzODViY3XscJMhcW5ic4XzdIVve2mxbjDjeYx1fXKncx?= M3T3b|I{QTd|OUm2
Colo 205 NIrBSVlHfW6ldHnvckBCe3OjeR?= NFLJU|IxNjBzNTFOwIcwdUx? MX:yOEBp MU\pcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFXSJJN1emW|cz3y[YxifGWmIHflcoV{ NX[4UIJEOjN7N{O5PVY>
Colo 205 NV22dFFRTnWwY4Tpc44hSXO|YYm= Mkf3NE4xOTVizsznM41N NG\B[pAzPCCq NETScplqdmirYnn0d{B1cGViYXP0bZZqfHlib3[gUW1Rew>? NH\4OYEzOzl5M{m5Oi=>
IBRS2 NIXUOJJHfW6ldHnvckBCe3OjeR?= M1vMOlUh|rypL33s NGHhPYYxNjViaB?= MUfEUXNQ NVjFdYd{\Gm|coXweJMhfGinIFXSS2lEKGGwZDDHc4xoccLi M4r3fVI{QTZ|NUO0
IBRS2 MkH5SpVv[3Srb36gRZN{[Xl? M1O5SFUh|rypL33s NXfhW5ZXOC53IHi= NEXhRo5FVVOR MVzlcohidmOnczDGUWRXKGmwZnXjeIlwdg>? NF3lUoMzOzl4M{WzOC=>
HeLa NFTCd|RHfW6ldHnvckBCe3OjeR?= MVKyJO69VQ>? NV;1PXZ6OiCqwrC= MWPheJRmdnWjdHXzJJRp\SCWTl[tbY5lfWOnZDDz[YNz\XSrb36gc4YhUUxvMUW= Mnu2NlM6PTB6OUK=
HFS  NVzjW5p2TnWwY4Tpc44hSXO|YYm= NV24bWllOC1zIN88[{9udA>? MVKyOEBp MofUS2xVWCCneIDy[ZN{cW:wIILlZYNp\XNiYTDwcIF1\WG3IHH0JINwdmOnboTyZZRqd26|IHHzJIxwfyCjczCwMlAyKML3Zz;tcC=> NVTB[lFNOjN6OUS2N|M>
HFS  NUfnZVFMTnWwY4Tpc44hSXO|YYm= MlPmNE4xOSEEtXevcYw> NULXXJE4OjRiaB?= NFHvR2pqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4Yh\2y7Y3;zdIhqdmexbHnwbYQhe3mwdHjhd4Uh\2WwZYOgZZQhPiCq M4DEOFI{QDl2NkOz
OVCAR-3 NV;4cFdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu4fIVQOeLCk{G1xsDPxE4EoB?= MmT6NlTDqGh? M4fTcIlv\HWlZYOgZUBtd3O|IH;mJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHoEoB?= MlLnNlM5OjZ7NkS=
OVCAR-3 MlrKSpVv[3Srb36gRZN{[Xl? M2j1O|HjiJNzNdMg{txOyqB? M3;pZVI1yqCq M4nrW4lv\HWlZYOgcpVkdGWjcjDkZY1i\2V? MnzCNlM5OjZ7NkS=
OVCAR-3 MYHBdI9xfG:|aYOgRZN{[Xl? NIjiSosyNTFywrFOwG0> M{PodlQhcA>? MVHpcoR2[2W|IITo[UBi[3SrdnH0bY9vKG:oIHHwc5B1d3Orcz3y[YxifGWmIIDyc5RmcW6| NUXGUHhkOjN6Mk[5OlQ>
OVCAR-3 NULmN3hlSXCxcITvd4l{KEG|c3H5 MoLpNVDDqM7:TR?= MViyOOKhcA>? MYnpcoR2[2W|IHHjeIl3[XSrb36gc4Yh[2G|cHHz[ZM> M1rIOVI{QDJ4OU[0
OVCAR-3 NYTKSmFnTnWwY4Tpc44hSXO|YYm= NIW0[5Iy6oDVMUFCpO69VQ>? M3zkWFI1yqCq NVvBbWNRcW6mdXPld{BlcXO{dYD0bY9vKG:oIITo[UBucXSxY3jvcoRzcWGuIITyZY5{dWWvYoLhcoUheG:2ZX70bYFt MkTBNlM5OjZ7NkS=
OVCAR-3 M3nQbWZ2dmO2aX;uJGF{e2G7 NGXEVWYy6oDVMUFCpO69VQ>? MVmyOOKhcA>? NX\JN2xCcW6mdXPld{Bnd3KvYYTpc44hd2ZicnXhZ5RqfmVib4j5[4VvKHOyZXPp[ZM> MUeyN|gzPjl4NB?=
OVCAR-3 Mm\rSpVv[3Srb36gRZN{[Xl? MVGx5qCUOTEEoN88US=> MWOyOOKhcA>? M332[olvcGmkaYTzJINmdGxiYXTo[ZNqd25iYX7kJI1q\3KjdHnvci=> MYqyN|gzPjl4NB?=
MKN45 M2XtOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfpNpBXUUN3MEywMlAxOSEQvHevcYw> NEXHS|UzOzd7M{O0Ni=>
LOVO MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMUKg{txoN22u MXmyN|c6OzN2Mh?=
A549 NEL6PG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzLcYlXUUN3ME2wMlA1KM7:Zz;tcC=> M{jyN|I{Pzl|M{Sy
MDA-MB-435 NV;wSlBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRDBwMECxJO69\y:vbB?= NF7NUVczOzd7M{O0Ni=>
HepG2 NGTxe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoKzTWM2ODxyLkCwNUDPxGdxbXy= Mm\WNlM4QTN|NEK=
HL-60 NXW4SYNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRDBwMECxJO69\y:vbB?= NYnCXXNvOjN5OUOzOFI>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:

[5]

+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products0

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID